What was interesting was Scott’s take on the Partnership arrangement and that PAR will see through the Phase 3 before potentially (my words) brokering a deal with a big Phama. Which is smart as they have taken the pain in doing a CR they may as well spend the monies to enable them to Broker a bigger slice of the ongoing pie... Hence those anticipating a big pharma deal will probably not see one till after Phase 3.
I have read people are concerned that management will sell out for a low ball offer.. I think PR has a firm belief in IPPS and I don’t think he would be agreeable to an offer that severely underestimates the future value of the revenue stream.
PAR Price at posting:
$3.59 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)